This year has been a record year for Biotech initial public offerings (IPOs), with total deal value already up by 58% compared with all of 2019.
Casdin goes all-in on the SPAC game with $385M offering
Two of biotech’s biggest trends — the rise of SPACs and the Scrooge McDuck piles of cash suddenly available to a life sciences company on New York trading floors — converged late Wednesday in one of the largest life sciences SPAC offerings yet: $385 million.